Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) registered a 5.21% increase, still its new closing price is 28.95% up from the company’s 1 year high of 0.64.It posted -1.96% losses in previous 5 sessions and is now the subject of 0 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 0 buy or better ratings. The 0 stock analysts following this company have an average price target at $3.00, with individual PT in the $3.00-$3.00 range. The shares moved at $0.20, implying that brokerage firms see shares losing about -61.54% in twelve months time.
Immune Pharmaceuticals, Inc. (IMNP) SEC Form 4 News
The stock is getting much attention these days as insiders are adding shares while they posted a 9.89% rise year to date. A Director at Immune Pharmaceuticals, Inc. (IMNP) acquired shares in a transaction closed on Wednesday January 04, 2017. Kazado Daniel bought 76,503 shares in the company at $0.19 each and collected $14,001 in proceeds. Kazado Daniel now owns 1,145,171 shares in the company after this transaction. A Director in the company, Kazado Daniel, disclosed a transaction on Friday December 16, 2016 that ended up paying $30,001 from the purchase of 161,377 shares at $0.19 per share.
Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) Upcoming Results on Tap
Immune Pharmaceuticals, Inc. will next provide financial results for the September 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.60 in that period. Sales during the quarter are predicted to arrive at $0.
Immune Pharmaceuticals, Inc. (IMNP) Brokerage Update
Over the last six months and over the last three months, the shares of Immune Pharmaceuticals, Inc. (IMNP), have changed -44.86% and -5.21%, respectively.
